Siemens introduces drug testing analyzer
Sept. 30, 2025—Siemens Healthineers has introduced the Atellica DT 250 benchtop analyzer, to help identify substance use, monitor therapeutic and immunosuppressant drugs, and perform serum toxicology testing.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Streck adds Accellix platform to CD-Chex Plus (RUO) control
Sept. 24, 2025—Accellix and Streck announced a strategic collaboration in which Streck has added the Accellix automated cell phenotyping platform to its CD-Chex Plus (RUO) control.
Roche mass spec test categorized as moderate complexity
Sept. 19, 2025—The Food and Drug Administration has categorized Roche’s Ionify 25-Hydroxy Vitamin D total assay as moderate complexity under the Clinical Laboratory Improvement Amendments of 1988.
Idylla CDx MSI test gets FDA premarket approval
Sept. 18, 2025—Biocartis’ Idylla CDx MSI test, developed in partnership with Bristol Myers Squibb, has received FDA premarket approval.
StatLab launches PiSmart S1 slide printer
Sept. 17, 2025—StatLab Medical Products has launched the PiSmart S1 single hopper slide printer.
Voicebrook, Gestalt offer fully speech-enabled DP solution
Sept. 12, 2025—Voicebrook’s VoiceOver Pro reporting platform now connects with Gestalt’s PathFlow digital pathology platform, giving pathologists the ability to navigate images and create reports entirely by voice.
Guardant, PathGroup partner to expand access to Shield test
Sept. 8, 2025—Guardant Health and PathGroup are partnering to expand access to Guardant’s FDA-approved Shield blood test.
Agilent expands Dako Omnis family
Sept. 5, 2025—Agilent Technologies has introduced three models to its Dako Omnis family of instruments—the Omnis 110, 165, and 165 Duo—designed to provide laboratories with the flexibility to tailor staining solutions according to volume, workflow, and diagnostic requirements.
Data on the utility of MeMed BV to be presented at ACEP25
Sept. 4, 2025—MeMed announced that several oral presentations at the American College of Emergency Physicians Scientific Assembly 2025, Sept. 7–10 in Salt Lake City, will showcase clinical evidence supporting the utility of MeMed BV, an FDA-cleared test that distinguishes between bacterial and viral infections based on the body’s immune response.
Qiagen launches QIAstat-Dx Rise
Sept. 2, 2025—Qiagen has launched QIAstat‑Dx Rise, a version of the QIAstat-Dx automated syndromic testing system.